Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 233

1.

High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.

Madan S, Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Rajkumar SV, Hogan WJ, Leung N, Grogan M, Gertz MA.

Blood. 2012 Feb 2;119(5):1117-22. doi: 10.1182/blood-2011-07-370031. Epub 2011 Dec 6.

2.

An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.

Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, Berk J, Quillen K, Skinner M.

Bone Marrow Transplant. 2001 Oct;28(7):637-42. Review.

3.

Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.

Scott EC, Heitner SB, Dibb W, Meyers G, Smith SD, Abar F, Kovacsovics T, Perez-Avraham G, Stentz A, Frires R, Dibb J, Maziarz RT.

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):424-430.e1. doi: 10.1016/j.clml.2014.02.003. Epub 2014 Feb 16.

PMID:
24650974
4.

Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP.

Hayashi T, Ikeda H, Igarashi T, Maruyama Y, Aoki Y, Nojima M, Ishida T, Shinomura Y.

Int J Hematol. 2014 Dec;100(6):554-8. doi: 10.1007/s12185-014-1680-1. Epub 2014 Oct 4.

PMID:
25281404
5.

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.

Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, Segal A, Ruberg F, Meier-Ewert H, Andrea NT, Sloan JM, Finn KT, Doros G, Blade J, Skinner M.

Blood. 2011 Oct 20;118(16):4346-52. doi: 10.1182/blood-2011-01-330738. Epub 2011 Aug 9.

6.

Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis.

Taimur S, Nader C, Lloyd-Travaglini C, Seldin DC, Sanchorawala V.

Transpl Infect Dis. 2013 Apr;15(2):187-94. doi: 10.1111/tid.12037. Epub 2012 Dec 20.

PMID:
23279695
7.

Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.

Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, Dember LM, Berk JL, Akpek G, LaValley M, O'hara C, Arkin CF, Wright DG, Skinner M.

Blood. 1998 May 15;91(10):3662-70.

8.

Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis.

Girnius S, Seldin DC, Skinner M, Finn KT, Quillen K, Doros G, Sanchorawala V.

Ann Hematol. 2010 Jun;89(6):579-84. doi: 10.1007/s00277-009-0874-8. Epub 2009 Dec 10.

PMID:
20012043
9.

Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.

Sanchorawala V, Brauneis D, Shelton AC, Lo S, Sun F, Sloan JM, Quillen K, Seldin DC.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1445-51. doi: 10.1016/j.bbmt.2015.04.001. Epub 2015 Apr 6.

10.

Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.

Perfetti V, Siena S, Palladini G, Bregni M, Di Nicola M, Obici L, Magni M, Brunetti L, Gianni AM, Merlini G.

Haematologica. 2006 Dec;91(12):1635-43.

11.

Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement.

Girnius S, Seldin DC, Meier-Ewert HK, Sloan JM, Quillen K, Ruberg FL, Berk JL, Doros G, Sanchorawala V.

Bone Marrow Transplant. 2014 Mar;49(3):434-9. doi: 10.1038/bmt.2013.192. Epub 2013 Dec 9.

PMID:
24317129
12.

Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65.

Seldin DC, Anderson JJ, Skinner M, Malek K, Wright DG, Quillen K, Finn K, Oran B, Sanchorawala V.

Blood. 2006 Dec 1;108(12):3945-7. Epub 2006 Aug 22.

13.

Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.

Leung N, Dispenzieri A, Fervenza FC, Lacy MQ, Villicana R, Cavalcante JL, Gertz MA.

Am J Kidney Dis. 2005 Aug;46(2):270-7. Review.

PMID:
16112045
14.

High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.

Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M, Linke RP, Ho AD, Goldschmidt H.

Br J Haematol. 2004 Dec;127(5):543-51.

PMID:
15566357
15.

Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma.

Novitzky N, Thomson J, Thomas V, du Toit C, Mohamed Z, McDonald A.

Biol Blood Marrow Transplant. 2010 Oct;16(10):1402-10. doi: 10.1016/j.bbmt.2010.04.002. Epub 2010 Apr 10.

16.

[Clinical analysis of autologous stem cell transplantation for nine cases of cardiac amyloidosis].

Ogura M, Sekine R, Nishiyama S, Abe Y, Iizuka H, Kusaka S, Nakagawa Y, Suzuki K.

Rinsho Ketsueki. 2012 Jul;53(7):710-5. Japanese.

PMID:
22975774
17.

High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis.

Kongtim P, Qazilbash MH, Shah JJ, Hamdi A, Shah N, Bashir Q, Wang M, Champlin R, Manasanch EE, Weber D, Orlowski RZ, Parmar S.

Bone Marrow Transplant. 2015 May;50(5):668-72. doi: 10.1038/bmt.2015.21. Epub 2015 Mar 2.

PMID:
25730192
18.

High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial.

Sanchorawala V, Wright DG, Seldin DC, Falk RH, Finn KT, Dember LM, Berk JL, Quillen K, Anderson JJ, Comenzo RL, Skinner M.

Bone Marrow Transplant. 2004 Feb;33(4):381-8.

PMID:
14676787
19.

High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center.

Tsai SB, Seldin DC, Quillen K, Berk JL, Ruberg FL, Meier-Ewert H, Sloan JM, Doros G, Finn KT, Skinner M, Sanchorawala V.

Blood. 2012 Nov 22;120(22):4445-6. doi: 10.1182/blood-2012-09-457341. No abstract available.

20.

High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.

Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, Recher C, Asli B, Lioure B, Royer B, Jardin F, Bridoux F, Grosbois B, Jaubert J, Piette JC, Ronco P, Quet F, Cogne M, Fermand JP; Myélome Autogreffe (MAG) and Intergroupe Francophone du Myélome (IFM) Intergroup.

N Engl J Med. 2007 Sep 13;357(11):1083-93.

Supplemental Content

Support Center